secwatch.observer — SEC 8-K summary
======================================

Issuer:     LISATA THERAPEUTICS, INC. (LSTA)
CIK:        0000320017
Form:       8-K
Filed at:   2022-09-14T23:59:59+00:00
Accession:  0000320017-22-000079
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 5.03, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caladrius stockholders approve merger with Cend Therapeutics, 1:15 reverse split, name change to Lisata Therapeutics
--------------------------------------------------------------------------------

- Merger with Cend approved: 25,973,235 for, 2,912,622 against, 172,676 abstain.
- Reverse stock split at 1:15 ratio approved: 31,343,168 for, 7,665,240 against.
- Name change to Lisata Therapeutics approved: 34,861,858 for, 4,003,401 against.
- Merger close expected Sep 15, 2022; combined company to trade as LSTA on Nasdaq.
- Board set reverse split ratio at 1:15; effective Sep 14, 2022 at 5:00 PM ET.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/320017/000032001722000079/0000320017-22-000079-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/320017/000032001722000079/clbs-20220913.htm
  HTML page:      https://secwatch.observer/filing/0000320017-22-000079

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer